Efficacy of cenobamate in tumor‐related epilepsy
This study demonstrates that adjunctive therapy with cenobamate treatment for TRE is a feasible and potentially effective option. Clinical history, including drug resistance, did not predict drug efficacy. No adverse effects were reported in those treated with chemotherapy. Further studies are needed to validate treatment response and safety.
Authors
- Katherine H. Noe (ORCID: https://orcid.org/0000-0002-9328-8546)
- Adrian Safa (ORCID: https://orcid.org/0000-0001-6297-4319)
- William O. Tatum (ORCID: https://orcid.org/0000-0002-4536-3791)
- Brin E. Freund (ORCID: https://orcid.org/0000-0001-7446-1983)
- Anteneh M. Feyissa (ORCID: https://orcid.org/0000-0002-9318-3947)
- David B. Burkholder (ORCID: https://orcid.org/0000-0001-9763-1025)
- Seyed M. Mirsattari (ORCID: https://orcid.org/0000-0002-5891-6295)
- Alfredo Quiñones-Hinojosa
- Guido Chiriboga
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- Mayo Clinic Hospital (US)
- Mayo Clinic in Florida (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Epileptic Disorders
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1002/epd2.70081
- Primary Topic
- Epilepsy research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00